Investigating and Resolving Cardiotoxicity Induced by COVID‐19 Treatments using Human Pluripotent Stem Cell‐Derived Cardiomyocytes and Engineered Heart Tissues

Investigating and Resolving Cardiotoxicity Induced by COVID‐19 Treatments using Human Pluripotent Stem Cell‐Derived Cardiomyocytes and Engineered Heart Tissues

Abstract Coronavirus disease 2019 continues to spread worldwide. Given the urgent need for effective treatments, many clinical trials are ongoing through repurposing approved drugs. However, clinical data regarding the cardiotoxicity of these drugs are limited. Human pluripotent stem cell‐derived ca...

Full description

Bibliographic Details
Main Authors: He Xu, Ge Liu, Jixing Gong, Ying Zhang, Shanshan Gu, Zhongjun Wan, Pengcheng Yang, Yage Nie, Yinghan Wang, Zhan‐peng Huang, Guanzheng Luo, Zhongyan Chen, Donghui Zhang, Nan Cao
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Advanced Science
Subjects:
cardiotoxicity
engineered heart tissue
high throughput screening
human pluripotent stem cell‐derived cardiomyocytes
repurposed drugs for COVID‐19
Online Access:https://doi.org/10.1002/advs.202203388

Internet

https://doi.org/10.1002/advs.202203388

Similar Items